the aid library

LIST OPTIONS

Filter

20981

Sort by:

Direction:

Download (141)

View PDF (96)

Overview of methods to assess population exposure to ambient air pollution
recommended

World Health Organization WHO (2023) C_WHO

This document summarizes several air quality measurement and modelling methods that can be used to estimate ground-level air pollutant concentrations and presents multiple approaches to monitoring ambient air pollution at different spatial and temporal scales. These methods are crucial for estimatin... more

Download (53)

View PDF (78)

Sources of Air Pollution are a global challenge we must tackle together

World Health Organization WHO (2023) C_WHO

Infographic

Download (105)

View PDF (107)

A Roadmap to combat postpartum haemorrhage between 2023 and 2030

World Health Organization WHO (2023) C_WHO

WHO today released its first roadmap to tackle postpartum haemorrhage (PPH) – defined as excessive bleeding after childbirth - which affects millions of women annually and is the world’s leading cause of maternal deaths. Despite being preventable and treatable, PPH results in around 70 000 de... more

Download (124)

View PDF (126)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 9 October 2023

World Health Organization WHO (2023) CC

The Infection prevention and control in the context of coronavirus disease 2019 (COVID-19): a living guideline consolidates technical guidance developed and published during the COVID-19 pandemic into evidence-informed recommendations for infection prevention and control (IPC). This living guideline... more

Download (59)

View PDF (56)

Tracking sectoral allocation of official development assistance: a comparative study of the 29 Development Assistance Committee countries, 2011–2018

Nomura S; Sakamoto H.; Ishizuka A. et al. Global Health Action (2021) CC

Official development assistance (ODA) is one of the most important means for donor countries to foster diplomatic relations with low- and middle-income countries and contribute to the welfare of the international community.Objective: This study estimated the sectoral allocation of

Download (55)

View PDF (194)

Violence against women

World Health Organisation (WHO) (2021) C_WHO

Fact Sheet

Download (56)

View PDF (50)

Voluntary contributions by fund and by contributor, 2018

World Health Organisation (WHO) (2019) C_WHO

Voluntary contributions by fund and by contributor, 2018

Download (94)

View PDF (97)

Towards a malaria-free world: elimination of malaria in Kyrgyzstan

World Health Organisation (WHO) (2023) C_WHO

This publication describes the reasons for the resurgence of malaria in Kyrgyzstan and presents an analysis of evidence-based elimination strategies and policies that were applied to contain the epidemic and outbreaks of the disease, achieve its elimination, and maintain the country malaria-free. Th... more

Download (96)

View PDF (68)

Promoting physical activity for older people: a toolkit for action

World Health Organisation (WHO) (2023) C_WHO

This ACTIVE toolkit provides evidence-based guidance on the key approaches to promote and enable older people to be physically active, regardless of who they are, where they live, or their intrinsic capacities (for example their visual or cognitive abilities) or whether they live with chronic condit... more

Download (83)

View PDF (86)

The use of next-generation sequencing for the surveillance of drug-resistant tuberculosis: an implementation manual

World Health Organisation (WHO) (2023) C_WHO

This document provides practical guidance on planning and implementing next-generation sequencing (NGS) technology for characterization of Mycobacterium tuberculosis complex (MTBC) bacteria. The aim is to detect mutations associated with drug resistance in the context of a surveillance system for tu... more

Download (57)

View PDF (80)

Tuberculosis action plan for the WHO European Region, 2023–2030

World Health Organisation (WHO) (2023) C_WHO

Tuberculosis (‎TB)‎ and particularly drug-resistant TB continue to represent major public health threats in the WHO European Region. This document details the Tuberculosis action plan for the WHO European Region 2023–2030 as well as its monitoring and evaluation framework and outlines the visi... more

Download (91)

View PDF (213)

Interventions d’autogestion de la santé et des droits sexuels et reproductifs pour faire progresser la couverture sanitaire universelle
recommended

World Health Organisation (WHO) (2023) C_WHO

Les interventions d’autosoins offrent un énorme potentiel pour renforcer l’action individuelle et réduire les inégalités en matière de santé en augmentant la disponibilité d’options de soins de santé accessibles, acceptables et abordables qui s’ajoutent aux services et soins reçus ... more

Download (95)

View PDF (206)

Intervenciones de autocuidado para la salud y los derechos sexuales y reproductivos a fin de avanzar con la cobertura sanitaria universal:

World Health Organisation (WHO) (2023) C_WHO

Las intervenciones de autocuidado ofrecen un enorme potencial para mejorar la autonomía individual y reducir las desigualdades sanitarias al aumentar la disponibilidad de opciones de atención sanitaria accesibles, aceptables y asequibles que se suman a los servicios y la atención recibidos en u... more

Download (74)

View PDF (80)

WHO Guide to conducting programme reviews for HIV, viral hepatitis and sexually transmitted infections

World Health Organization WHO (2023) C_WHO

Sound periodic programme reviews provide opportunities for countries to objectively assess progress and take corrective action to sustain or get back on track towards achieving their medium and long-term programme goals. It reflects people’s diverse needs, enables efficient use of health system re... more

Download (71)

View PDF (87)

Pre-referral treatment with rectal artesunate of children with suspected severe malaria: a field guide

World Health Organization WHO (2023) C_WHO

Prompt, effective antimalarial treatment, and supportive care can substantially reduce the rate of mortality from severe malaria. However, many children in malaria-endemic countries do not have access to health facilities or a qualified health care provider and do not receive the necessary care in a... more

Download (176)

View PDF (247)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (80)

View PDF (69)

Roadmap towards ending TB in children and adolescents, 3rd ed

World Health Organisation (WHO) (2023) C_WHO

The Roadmap towards ending TB among children and adolescents, third edition builds on the 2013 and 2018 versions. The 2023 version recognizes the progress made over the past five years and outlines priorities and key actions designed to accelerate progress towards the targets elaborated during the 2... more

Download (81)

View PDF (75)

Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance, 2nd ed

World Health Organisation (WHO) (2023) C_WHO

Of the more than 10 million people estimated to have fallen ill with tuberculosis (TB) in 2022, just over 400 000 people developed TB resistant to rifampicin (RIF), and 1.3 million people developed TB resistant isoniazid (INH). Drug resistance must be detected rapidly and accurately to initiate appr... more

Download (84)

View PDF (82)

Zanzibar's victory against Cholera Epidemic

World Health Organization WHO (2023) C_WHO

Response to the Periodic Epidemic

Overview of methods to assess population exposure to ambient air pollution recommended

Interventions d’autogestion de la santé et des droits sexuels et reproductifs pour faire progresser la couverture sanitaire universelle recommended

Overview of methods to assess population exposure to ambient air pollution
recommended

Interventions d’autogestion de la santé et des droits sexuels et reproductifs pour faire progresser la couverture sanitaire universelle
recommended